BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Vote in favor of your #1 Kind of Cap - 2Top 10 Books That Will Have an impact on Your Viewpoint
- 3From Exemplary to Current: Famous Rings Available
- 4Understanding climate change in America: Skepticism, dogmatism and personal experience
- 5What causes RFK Jr.’s strained and shaky voice? A neurologist explains this little-known disorder
- She just became the first wheelchair user to travel to space
- Top Fascinating Organic products: Which One Might You Want to Attempt?
- People who talk with their hands seem more clear and persuasive – new research
- Tech Devices 2023: The Most blazing Arrivals of the Year
- James Webb Space Telescope's mysterious 'little red dots' may be black holes in disguise
- Experiences in Natural life Protection: Individual Progressives' Excursions
- Figure out What Shift Differentials Mean for Your General Attendant Compensation
- The Most Vital Crossroads in Olympic History
- Smooth out Your Funds: Cash The board Simplified
